We consult, write, and speak on critical issues that determine the success of life science companies. Working together with our partners in the Biopharmaceutical Consortium and Innovalyst, we help your company increase the effectiveness of its drug and diagnostic discovery and development, commercialization of new research products, assessment of new business opportunities, and partnering.
Our typical consulting engagements have included:
- Strategic new product and R&D planning
- Opportunity assessment and assistance in partnering
- Technology assessment
- Assessment of pipeline drugs and assistance in go/no go decisions
- Proprietary strategic reports on areas for potential business expansion
- Due diligence on potential partners and investment or acquisition candidates
For further details on consulting services we have provided, please read more
From startups to major corporations, our clients principally include:
- pharmaceutical companies
- biotechnology companies
- diagnostics companies
- research products companies
We serve clients on a worldwide basis, mainly in North America, Europe, and Japan.
Our books and reports have been published by such leading organizations as Decision Resources, Cambridge Healthtech Institute, and Informa Healthcare.
Our articles have appeared in such leading publications as Genetic Engineering & Biotechnology News, Pharma DD, and PharmaWeek. See our articles page for examples.
We also publish articles on our Biopharmconsortium Blog, which we started in July 2009.
Our principal, Allan B. Haberman, has been quoted in such publications as BusinessWeek, Chemical & Engineering News, Mass High Tech, Nature Biotechnology, New Scientist, Pharmaceutical Executive, and Sacramento Business Journal.
We also speak and teach in business and academic settings.
Haberman Associates is a member of the Institute of Management Consultants (IMC). We subscribe to the IMC code of ethics, and strive to uphold high ethical standards as well as excellence in client service and in expert advice and counsel.